KV PHARMACEUTICAL ANNOUNCES APPROVALS FOR GYNAZOLE-1

KV Pharmaceutical has announced that it has received notification of approvals to market Gynazole-1 from one of its international licensees, Gedeon Richter.

Gedeon Richter is the third international licensee of KV Pharmaceutical to submit an application and receive approval for Gynazole-1, a one-dose prescription cream treatment for vaginal yeast infections from Candida. To date, Gedeon Richter has received approval to market Gynazole-1 in 15 of its 21 Eastern European countries and territories.